Metronomic chemotherapy
Open Access
- 1 September 2014
- journal article
- review article
- Published by SAGE Publications in Journal of Pharmacology and Pharmacotherapeutics
- Vol. 5 (3) , 186-192
Abstract
Toxic effects and chemoresistance are major hurdles in chemotherapy and to avoid these problems caused by traditional chemotherapeutic regimens, a new modality of drug administration called "metronomic chemotherapy" has emerged. Such regimen involves the frequent administration of conventional chemotherapeutic agents at very low doses to target activated endothelial cells in tumors, the advantages of which include minimal adverse effects and a rare chance of developing acquired drug resistance. Previously it was thought that they act by targeting angiogenesis, but recently additional mechanisms have been discovered which has established metronomic chemotherapy as a type of multi-targeted therapy. The knowledge gained from the preclinical studies of metronomic chemotherapy, along with clinical experience, will help to design better therapeutic protocols against cancer. Detailed pharmacogenomic and pharmacoproteomic studies on tumor endothelial cells and large multi-centered clinical trials, integrating bio-marker analyzes, are needed to investigate and validate the best treatment combinations for each tumor type and patient population.Keywords
This publication has 40 references indexed in Scilit:
- Metronomic Chemotherapy in Progressive Pediatric Malignancies: Old Drugs in New PackageIndian Journal of Pediatrics, 2012
- Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer TreatmentCurrent Cancer Drug Targets, 2007
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs.2002
- Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in miceJournal of Clinical Investigation, 2000
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityJournal of Clinical Investigation, 2000
- Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.2000
- Back to the basics: the importance of concentration x time in oncology.Journal of Clinical Oncology, 1993
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971